NASDAQ : DRUG

Bright Minds Biosciences Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 54.98 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 544.36M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

Details

NameBright Minds Biosciences Inc.
SectorHealthcare
IndustryBiotechnology
Employees26
Founded2019
CeoIan McDonald
CountryUnited States
ExchangeNASDAQ
Fiscal YearOctober - September
Reporting CurrencyCAD
IsinCA10919W4056
Cusip10919W405
Cik1827401
Sic2834

Key executives

NameTitle
Ian McDonaldCo-Founder, Chief Executive Officer, President and Director
Ryan E. S. K. Cheung B.Com., C.A., CPAChief Financial Officer and Corporate Secretary
Dr. Jan Torleif Pedersen M.Sc., Ph.D.Chief Science Officer and Director
Alex VasilkevichChief Operating Officer and Senior Scientific Officer
Dr. Emer Leahy M.B.A., Ph.D.Consultant
Dr. Stephen D. Collins M.D., Ph.D.Chief Medical Officer

Contact

Address19 Vestry Street, New York, New York 10013, United States
Phone647 865 8622
Websitehttps://brightmindsbio.com